EGFR and adenocarcinoma: Non-adenocarcinoma patients harboring EGFR mutations had significantly shorter DFS and OS compared to EGFR-mutated adenocarcinoma patients (15.0 versus 39.0 months, log-rank χ2 = 15.075, P < 0.001 for DFS; 30.1 versus 62.6 months, log-rank χ2 = 32.665, P < 0.001 for OS).